Plain-English translation of NCT03808922 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new antiviral medication called to see if it can help treat serious lower respiratory tract infections caused by parainfluenza and other related viruses in people with weakened immune systems. Patients with conditions like cancer, organ transplants, or stem cell transplants are at high risk for severe complications from these infections, and this medication is designed to help their bodies fight the virus more effectively. The study will also test the medication in people with severe COVID-19.
People with weakened immune systems—such as those being treated for cancer or who have received organ transplants—have very few treatment options when they develop serious respiratory infections. This medication may help reduce the severity of illness and improve survival in these vulnerable patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either receive the new medication or a placebo (inactive treatment) for 7 to 10 days. If you receive the medication, you will take it by mouth once or twice daily, depending on which group you are in. Throughout the study, the research team will monitor your oxygen levels, breathing, and overall health to see how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States